Novo Nordisk
↗Bagsværd, Denmark
Novo Nordisk is a leading global healthcare company headquartered in Bagsværd, Denmark, with operations spanning diabetes care, obesity management, cardiovascular diseases, rare blood disorders, and emerging therapeutic areas. Founded through the 1989 merger of Novo Industri A/S and Nordisk Gentofte A/S, the company has evolved from the world's largest insulin producer to a diversified biopharmaceutical company. The company produces nearly half of the world's insulin and is a market leader in GLP-1 receptor agonist therapies, with blockbuster drugs including Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral diabetes treatment). Novo Nordisk operates manufacturing facilities across nine countries and maintains a robust R&D pipeline focused on addressing serious chronic diseases through innovative therapeutic modalities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$42B-$46B
Founded:1989
Ownership:public
Status:operating
FUNDING
Investors:Novo Nordisk Foundation (via Novo Holdings A/S: 28.05% share capital, 77.28% voting rights)
STOCK
Exchange:NYSE
Ticker:NVO
Market Cap:$232.79B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 and Commercial
Modalities:Small molecules, Peptides and Proteins, GLP-1 Receptor Agonists, Amylin Analogues, mAbs (Monoclonal Antibodies), siRNA (Small Interfering RNA), Gene Editing/Genome Editing, Cell Therapy, ADCs (Antibody-Drug Conjugates)
Active Trials:150
Trial Phases:Phase 3: 15
FDA Approvals:38
EMA Approvals:35
CORPORATE STRUCTURE
Parent Company:Novo Nordisk Foundation (via Novo Holdings A/S)
Subsidiaries:83+ active subsidiaries globally across North America, Europe, Asia, Latin America, Africa, Middle East, and Australia, Recent additions: Catalent manufacturing sites (Anagni Italy, Bloomington Indiana, Brussels Belgium) acquired December 2024, Novavax Czech Republic manufacturing site
Key Partnerships:NVIDIA (AI drug discovery collaboration using Gefion sovereign AI supercomputer), Life Edit Therapeutics (gene editing technologies for genetic disorders), NanoVation Therapeutics (genetic medicines for cardiometabolic and rare diseases), Gensaic (next-generation precision therapies), Evotec (cell therapy technology development), Heartseed (cell therapy for heart failure), Ventus Therapeutics (small molecules for cardiovascular disease)
COMPETITION
Position:Leader
Competitors:Eli Lilly (Mounjaro/tirzepatide, Zepbound - major threat in diabetes/obesity), Roche (Hemlibra - competes in haemophilia), Pfizer (emerging GLP-1 candidates, owns Vyndaqel), Sanofi (GLP-1 pipeline), Amgen (GLP-1 candidates), AstraZeneca (GLP-1 candidates), Generic/Compounding pharmacies (copycat GLP-1 compounds)
LEADERSHIP
Key Executives:
Maziar Mike Doustdar - President and Chief Executive Officer
Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer
Martin Holst Lange - Executive Vice President of Research & Development and Chief Scientific Officer
Monique Carter - Executive Vice President and Head of People & Organisation
Lars Fruergaard Jørgensen - Former President and Chief Executive Officer
Scientific Founders:August Krogh, Marie Krogh, Hans Christian Hagedorn, Harald Pedersen, Thorvald Pedersen
Board Members:Henrik Poulsen (Chairman), Kasim Kutay (Board Member), Elisabeth Dahl Christensen (Board Member (Employee-elected)), Liselotte Hyveled (Board Member (Employee-elected)), Mette Bøjer Jensen (Board Member (Employee-elected)), Thomas Rantzau (Board Member (Employee-elected)), Lars Rebien Sørensen (Proposed Chair (Novo Nordisk Foundation proposal)), Cees de Jong (Proposed Vice Chair (Novo Nordisk Foundation proposal)), Britt Meelby Jensen (Proposed Board Member (Novo Nordisk Foundation proposal)), Mikael Dolsten (Proposed Board Member (Novo Nordisk Foundation proposal)), Stephan Engels (Proposed Board Member (Novo Nordisk Foundation proposal))
LINKS
Website:novonordisk.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Novo Nordisk. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.